JP2017516848A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516848A5 JP2017516848A5 JP2017513324A JP2017513324A JP2017516848A5 JP 2017516848 A5 JP2017516848 A5 JP 2017516848A5 JP 2017513324 A JP2017513324 A JP 2017513324A JP 2017513324 A JP2017513324 A JP 2017513324A JP 2017516848 A5 JP2017516848 A5 JP 2017516848A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aqueous pharmaceutical
- arginine
- suitably
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000007979 citrate buffer Substances 0.000 claims 11
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 10
- 229960002964 adalimumab Drugs 0.000 claims 9
- 239000004475 Arginine Substances 0.000 claims 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 8
- 235000009697 arginine Nutrition 0.000 claims 8
- 239000008363 phosphate buffer Substances 0.000 claims 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 6
- 239000000600 sorbitol Substances 0.000 claims 6
- 235000010356 sorbitol Nutrition 0.000 claims 6
- 239000003381 stabilizer Substances 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 5
- 239000004386 Erythritol Substances 0.000 claims 5
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 5
- 229930064664 L-arginine Natural products 0.000 claims 5
- 235000014852 L-arginine Nutrition 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 5
- 235000019414 erythritol Nutrition 0.000 claims 5
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 5
- 229940009714 erythritol Drugs 0.000 claims 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 5
- 229960000367 inositol Drugs 0.000 claims 5
- 239000000832 lactitol Substances 0.000 claims 5
- 235000010448 lactitol Nutrition 0.000 claims 5
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 5
- 229960003451 lactitol Drugs 0.000 claims 5
- 239000000845 maltitol Substances 0.000 claims 5
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 5
- 235000010449 maltitol Nutrition 0.000 claims 5
- 229940035436 maltitol Drugs 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 5
- 229940068977 polysorbate 20 Drugs 0.000 claims 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 5
- 239000000811 xylitol Substances 0.000 claims 5
- 235000010447 xylitol Nutrition 0.000 claims 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 5
- 229960002675 xylitol Drugs 0.000 claims 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 238000001962 electrophoresis Methods 0.000 claims 1
- 238000001155 isoelectric focusing Methods 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 230000006432 protein unfolding Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 150000005846 sugar alcohols Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021055560A JP2021107399A (ja) | 2014-05-23 | 2021-03-29 | 液体医薬組成物 |
| JP2022130994A JP2022174082A (ja) | 2014-05-23 | 2022-08-19 | 液体医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14169755.7A EP2946767B1 (en) | 2014-05-23 | 2014-05-23 | Liquid pharmaceutical composition |
| EP14169755.7 | 2014-05-23 | ||
| PCT/EP2015/060818 WO2015177059A1 (en) | 2014-05-23 | 2015-05-15 | Liquid pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021055560A Division JP2021107399A (ja) | 2014-05-23 | 2021-03-29 | 液体医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017516848A JP2017516848A (ja) | 2017-06-22 |
| JP2017516848A5 true JP2017516848A5 (Direct) | 2018-06-21 |
Family
ID=50774706
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513324A Withdrawn JP2017516848A (ja) | 2014-05-23 | 2015-05-15 | 液体医薬組成物 |
| JP2021055560A Withdrawn JP2021107399A (ja) | 2014-05-23 | 2021-03-29 | 液体医薬組成物 |
| JP2022130994A Pending JP2022174082A (ja) | 2014-05-23 | 2022-08-19 | 液体医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021055560A Withdrawn JP2021107399A (ja) | 2014-05-23 | 2021-03-29 | 液体医薬組成物 |
| JP2022130994A Pending JP2022174082A (ja) | 2014-05-23 | 2022-08-19 | 液体医薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10426833B2 (Direct) |
| EP (4) | EP2946767B1 (Direct) |
| JP (3) | JP2017516848A (Direct) |
| CN (2) | CN106535935A (Direct) |
| AU (3) | AU2015263247A1 (Direct) |
| CA (2) | CA3104940A1 (Direct) |
| CY (1) | CY1124493T1 (Direct) |
| DK (3) | DK3145488T3 (Direct) |
| ES (2) | ES2607489T3 (Direct) |
| HK (1) | HK1231391A1 (Direct) |
| HR (1) | HRP20201242T1 (Direct) |
| HU (1) | HUE050779T2 (Direct) |
| IL (2) | IL277241B (Direct) |
| LT (1) | LT3145488T (Direct) |
| PT (1) | PT3145488T (Direct) |
| RS (1) | RS60801B1 (Direct) |
| SI (1) | SI3145488T1 (Direct) |
| SM (1) | SMT202000479T1 (Direct) |
| WO (1) | WO2015177059A1 (Direct) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2946765B1 (en) * | 2014-05-23 | 2016-08-31 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| CN105543204A (zh) * | 2015-12-30 | 2016-05-04 | 海口奇力制药股份有限公司 | 一种组合物及其应用、含有该组合物的稳定剂 |
| US10874626B2 (en) | 2016-04-07 | 2020-12-29 | Nevakar Inc. | Formulation for use in a method of treatment of pain |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018193471A1 (en) * | 2017-04-18 | 2018-10-25 | Dr. Reddy's Laboratories Limited | Stable liquid pharmaceutical composition |
| CA3075414A1 (en) | 2017-10-03 | 2019-04-11 | Nevakar Inc. | Acetaminophen-pregabalin combinations and methods of treating pain |
| MX2017016884A (es) * | 2017-12-19 | 2019-06-20 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina anti-tnfa. |
| JP7457704B2 (ja) * | 2018-07-20 | 2024-03-28 | モメンタ ファーマシューティカルズ インコーポレイテッド | Ｆｃｒｎ抗体の組成物およびその使用の方法 |
| CR20210076A (es) | 2018-07-20 | 2021-09-02 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpo fcrn |
| CN113134081A (zh) * | 2020-01-20 | 2021-07-20 | 上海君实生物医药科技股份有限公司 | 抗btla抗体药物组合物及其用途 |
| KR20250077505A (ko) * | 2022-10-07 | 2025-05-30 | 애넥슨, 인코포레이티드 | 항-c1q 항체를 위한 제형 |
| CN117257936A (zh) * | 2023-10-30 | 2023-12-22 | 海正生物制药有限公司 | 一种阿达木单抗组合物 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6388197A (ja) | 1986-09-30 | 1988-04-19 | Tosoh Corp | モノクロナル抗体の安定化方法 |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| US5900404A (en) | 1997-08-15 | 1999-05-04 | Amgen Inc. | Chemical modification of proteins to improve biocompatibility and bioactivity |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| SI2335725T1 (sl) | 2003-04-04 | 2017-01-31 | Genentech, Inc. | Visokokoncentrirane formulacije protiteles in proteinov |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| WO2006012500A2 (en) | 2004-07-23 | 2006-02-02 | Genentech, Inc. | Crystallization of antibodies or fragments thereof |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RS52861B (sr) | 2005-06-07 | 2013-12-31 | Esbatech - A Novartis Company Llc | Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa) |
| KR20210049186A (ko) * | 2007-11-30 | 2021-05-04 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| AR073997A1 (es) * | 2008-10-29 | 2010-12-15 | Wyeth Corp | Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit |
| SG10201401995UA (en) * | 2009-05-04 | 2014-08-28 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| AU2011219715B2 (en) * | 2010-02-26 | 2014-12-11 | Novo Nordisk A/S | Stable antibody containing compositions |
| AU2011223805B2 (en) | 2010-03-01 | 2015-10-29 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| LT2637690T (lt) | 2010-11-11 | 2016-10-25 | Abbvie Biotechnology Ltd | Didelės koncentracijos anti-tnfalfa antikūno skystos kompozicijos |
| EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| DK2726090T3 (da) | 2011-07-01 | 2020-01-20 | Biogen Ma Inc | Argininfri tnfr: fc-fusionspolypeptidsammensætninger |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| WO2013164837A1 (en) * | 2012-03-07 | 2013-11-07 | Cadila Healthcare Limited | Pharmaceutical formulations of tnf-alpha antibodies |
| US20150150982A1 (en) | 2012-06-12 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| PT2892550T (pt) | 2012-09-07 | 2020-03-27 | Coherus Biosciences Inc | Formulações aquosas estáveis de adalimumab |
| AU2013334740A1 (en) | 2012-10-25 | 2015-04-02 | Medimmune, Llc | Stable, low viscosity antibody formulation |
| JP6339578B2 (ja) | 2012-10-31 | 2018-06-06 | タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤 |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| EP2727602A1 (en) | 2012-10-31 | 2014-05-07 | Takeda GmbH | Method for preparation of a high concentration liquid formulation of an antibody |
| CN105431453A (zh) | 2012-11-01 | 2016-03-23 | 艾伯维公司 | 稳定的双重可变结构域免疫球蛋白制剂 |
| CN104707146B (zh) | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
| EP3125928A4 (en) | 2014-04-02 | 2017-11-29 | Intas Pharmaceuticals Ltd. | Liquid pharmaceutical composition of adalimumab |
| EP2946765B1 (en) * | 2014-05-23 | 2016-08-31 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
-
2014
- 2014-05-23 ES ES14169755.7T patent/ES2607489T3/es active Active
- 2014-05-23 EP EP14169755.7A patent/EP2946767B1/en not_active Not-in-force
-
2015
- 2015-05-15 HR HRP20201242TT patent/HRP20201242T1/hr unknown
- 2015-05-15 WO PCT/EP2015/060818 patent/WO2015177059A1/en not_active Ceased
- 2015-05-15 IL IL277241A patent/IL277241B/en unknown
- 2015-05-15 JP JP2017513324A patent/JP2017516848A/ja not_active Withdrawn
- 2015-05-15 US US15/313,487 patent/US10426833B2/en active Active
- 2015-05-15 SI SI201531313T patent/SI3145488T1/sl unknown
- 2015-05-15 EP EP15723695.1A patent/EP3145488B1/en active Active
- 2015-05-15 CA CA3104940A patent/CA3104940A1/en not_active Abandoned
- 2015-05-15 CA CA2948746A patent/CA2948746C/en active Active
- 2015-05-15 PT PT157236951T patent/PT3145488T/pt unknown
- 2015-05-15 RS RS20201035A patent/RS60801B1/sr unknown
- 2015-05-15 HK HK17105117.8A patent/HK1231391A1/zh unknown
- 2015-05-15 EP EP21175530.1A patent/EP3939566A1/en active Pending
- 2015-05-15 HU HUE15723695A patent/HUE050779T2/hu unknown
- 2015-05-15 LT LTEP15723695.1T patent/LT3145488T/lt unknown
- 2015-05-15 SM SM20200479T patent/SMT202000479T1/it unknown
- 2015-05-15 DK DK15723695.1T patent/DK3145488T3/da active
- 2015-05-15 CN CN201580039972.4A patent/CN106535935A/zh active Pending
- 2015-05-15 ES ES15723695T patent/ES2815598T3/es active Active
- 2015-05-15 CN CN202010856565.5A patent/CN111939257A/zh active Pending
- 2015-05-15 EP EP20186550.8A patent/EP3741358A1/en not_active Withdrawn
- 2015-05-15 AU AU2015263247A patent/AU2015263247A1/en not_active Abandoned
-
2016
- 2016-11-22 IL IL249116A patent/IL249116B/en active IP Right Grant
-
2019
- 2019-09-26 US US16/584,418 patent/US20200155677A1/en not_active Abandoned
-
2020
- 2020-04-08 DK DKBA202000030U patent/DK202000030Y3/da active IP Right Grant
- 2020-05-14 DK DKBA202000038U patent/DK202000038Y3/da not_active IP Right Cessation
- 2020-06-26 AU AU2020204269A patent/AU2020204269B2/en not_active Ceased
- 2020-09-08 CY CY20201100843T patent/CY1124493T1/el unknown
- 2020-12-10 AU AU2020286276A patent/AU2020286276B2/en not_active Expired - Fee Related
-
2021
- 2021-03-29 JP JP2021055560A patent/JP2021107399A/ja not_active Withdrawn
-
2022
- 2022-08-19 JP JP2022130994A patent/JP2022174082A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516848A5 (Direct) | ||
| JP2017516847A5 (Direct) | ||
| HRP20181226T1 (hr) | Tekući farmaceutski sustav | |
| RU2016150640A (ru) | Жидкая фармацевтическая композиция | |
| JP2012211150A5 (Direct) | ||
| JP2019504086A5 (Direct) | ||
| NZ730821A (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| RU2015132431A (ru) | Составы, содержащие антитела | |
| JP2024001364A5 (Direct) | ||
| JP2013543505A5 (Direct) | ||
| RU2013148119A (ru) | Лиофилизированный препарат ботулотоксина | |
| CY1124493T1 (el) | Υγρη φαρμακευτικη συνθεση | |
| FI3479819T3 (fi) | Stabiili nestemäinen farmaseuttinen valmiste | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| JP2019536761A5 (Direct) | ||
| JP2018528242A5 (Direct) | ||
| RU2019116756A (ru) | Жидкая фармацевтическая композиция | |
| RU2017101667A (ru) | Фармацевтические композиции | |
| AR103544A1 (es) | FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a | |
| JP2015535237A5 (Direct) | ||
| JP2019509311A5 (Direct) | ||
| JP2018532806A5 (Direct) |